• Joel N Buxbaum, David S Eisenberg, Marcus Fändrich, Ellen D McPhail, Giampaolo Merlini, Maria J M Saraiva, Yoshiki Sekijima, and Per Westermark.
• Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
• Amyloid. 2024 Sep 30: 181-8.

AbstractThe ISA Nomenclature Committee met at the XIX International Symposium of Amyloidosis in Rochester, MN, 27 May 2024. The in-person event was followed by many electronic discussions, resulting in the current updated recommendations. The general nomenclature principles are unchanged. The total number of human amyloid fibril proteins is now 42 of which 19 are associated with systemic deposition, while 4 occur with either localised or systemic deposits. Most systemic amyloidoses are caused by the presence of protein variants which promote misfolding. However, in the cases of AA and ATTR the deposits most commonly consist of wild-type proteins and/or their fragments. One peptide drug, previously reported to create local iatrogenic amyloid deposits at its injection site, has been shown to induce rare instances of systemic deposition. The number of described animal amyloid fibril proteins is now 16, 2 of which are unknown in humans. Recognition of the importance of intracellular protein aggregates, which may have amyloid or amyloid-like properties, in many neurodegenerative diseases is rapidly increasing and their significance is discussed.

6 keywords...

hide…